Biokin Pharmaceutical is a biopharmaceutical company dedicated to the forefront of global biomedical innovation, with a strategic focus on addressing unmet clinical needs. The company has established world-leading capabilities in large-molecule oncology therapeutics (ADC/GNC/ARC), encompassing cutting-edge research and development, global clinical development, and large-scale manufacturing and supply. Biokin is steadily advancing toward becoming a fully integrated multinational biopharmaceutical enterprise with global commercialization capabilities. Adhering to the strategic positioning of “Rooted in China, Oriented toward Globalization, and Becoming a Multinational Corporation (MNC),” the company is committed to becoming a multinational pharmaceutical company with a global leadership advantage in oncology therapeutics.

Biokin maintains R&D centers in both China and the United States, namely SystImmune in Seattle, USA, and Baili Pharma R&D Center and DotBio R&D Center in Chengdu, Sichuan, China. These centers work in close collaboration to drive innovative therapies from early discovery through clinical application, ensuring robust, efficient, and globally relevant drug development. The company operates four manufacturing facilities: Guorui Pharmaceutical, specializing in injectables and oral formulations; Baili Pharma, focusing on oral solid dosage forms and lyophilized injectables; Haiyate / Jingxi Pharmaceutical, dedicated to intermediates and active pharmaceutical ingredients (APIs); and DotBio, concentrating on innovative medicines.